Therapy of low-grade nonmuscle-invasive bladder cancer

被引:0
|
作者
Olbert, P. J. [1 ]
Ohlmann, C. H. [2 ]
Schwentner, C. [3 ]
机构
[1] Univ Klinikum Giessen & Marburg GmbH, Prostatakarzinomzentrum, Comprehens Canc Ctr Marburg, Klin Urol & Kinderurol, D-35043 Marburg, Germany
[2] Univ Saarlandes Kliniken, Klin Urol & Kinderurol, Homburg, Germany
[3] Univ Tubingen, Univ Klin Urol, Tubingen, Germany
来源
UROLOGE | 2015年 / 54卷 / 04期
关键词
Instillation protocol; Urine-based markers; Cytology; Neoplasm recurrence; local; Biological markers; HEXAMINOLEVULINATE FLUORESCENCE CYSTOSCOPY; BAND IMAGING CYSTOSCOPY; WHITE-LIGHT CYSTOSCOPY; BACILLUS-CALMETTE-GUERIN; CARCINOMA IN-SITU; TRANSURETHRAL RESECTION; PHASE-III; UROTHELIAL CARCINOMA; TUMOR RECURRENCE; URINARY CYTOLOGY;
D O I
10.1007/s00120-015-3773-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Nonmuscle-invasive bladder cancer (NMIBC) comprises a very heterogeneous group of malignancies; the biological behavior of these tumors depends primarily on their grading. Low-grade NMIBC are characterized by a high propensity for recurrence but a very low risk for progression to muscle invasion or metastatic disease. Thus, the first line goal of diagnostic procedures and therapy is reliable visualization and complete resection of all foci. Cytology and other urine-based markers fail due to insufficient sensitivity. A second resection might be necessary only in selected intermediate risk cases; the positive effect of maintenance instillation protocols beyond a single postoperative instillation is questionable for the majority of patients. Risk stratification, e.g., according to the EORTC or EAU proposals, also makes sense in low grade NMIBC.
引用
收藏
页码:484 / 490
页数:7
相关论文
共 50 条
  • [1] Perioperative management of nonmuscle-invasive bladder cancer
    Falke, Johannes
    Witjes, J. Alfred
    CURRENT OPINION IN UROLOGY, 2011, 21 (05) : 403 - 408
  • [2] Therapie des nicht-muskelinvasiven Low-grade-HarnblasenkarzinomsTherapy of low-grade nonmuscle-invasive bladder cancer
    P.J. Olbert
    C.H. Ohlmann
    C. Schwentner
    Der Urologe, 2015, 54 (4): : 484 - 490
  • [3] Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review
    Mori, Keiichiro
    Miura, Noriyoshi
    Babjuk, Marek
    Karakiewicz, Pierre, I
    Mostafaei, Hadi
    Laukhtina, Ekaterina
    Quhal, Fahad
    Motlagh, Reza Sari
    Pradere, Benjamin
    Kimura, Shoji
    Egawa, Shin
    Shariat, Shahrokh F.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (10) : 774 - 782
  • [5] Update on the role of endovesical chemotherapy in nonmuscle-invasive bladder cancer
    Unda-Urzaiz, M.
    Fernandez-Gomez, J. M.
    Cozar-Olmos, J. M.
    Juarez, A.
    Palou, J.
    Martinez-Pineiro, L.
    ACTAS UROLOGICAS ESPANOLAS, 2018, 42 (02): : 73 - 76
  • [6] Nonmuscle-invasive bladder cancer, old problems, new insights
    Comperat, Eva
    Wasinger, Gabriel
    Oszwald, Andre
    Pradere, Benjamin
    Shariat, Shahrokh
    CURRENT OPINION IN UROLOGY, 2022, 32 (04) : 352 - 357
  • [7] Diagnostics of nonmuscle-invasive urothelial cell carcinoma of the bladder
    Tschirdewahn, S.
    vom Dorp, F.
    UROLOGE, 2015, 54 (04): : 480 - 483
  • [8] An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer
    Daniels, Marcus J.
    Barry, Emily
    Milbar, Niv
    Schoenberg, Mark
    Bivalacqua, Trinity J.
    Sankin, Alex
    Kates, Max
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (02) : 40.e17 - 40.e24
  • [9] Indication for early cystectomy in nonmuscle-invasive bladder cancer. Literature review
    Cogorno Wasylkowski, L.
    Rios-Gonzalez, E.
    Linares Espinos, E.
    Leibar Tamayo, A.
    Martinez-Pineiro Lorenzo, L.
    ACTAS UROLOGICAS ESPANOLAS, 2018, 42 (01): : 17 - 24
  • [10] Apaziquone for Nonmuscle Invasive Bladder Cancer Where Are We Now?
    Arends, Tom J. H.
    Witjes, Johannes Alfred
    UROLOGIC CLINICS OF NORTH AMERICA, 2020, 47 (01) : 73 - +